A Pilot Study to Examine the Effects of Smoking Cessation on Serum Markers of Inflammation in Women at Risk for Cardiovascular Disease

Overview

Journal Chest

Publisher Elsevier

Specialty Pulmonary Medicine

Date 2009 Feb 20

PMID 19225057

Citations 21

Authors

Virginia Reichert

Xiangying Xue

Diane Bartscherer

Daniel Jacobsen

Christine Fardellone

Patricia Folan

Nina Kohn

Arunabh Talwar

Christine N Metz

Affiliations

Soon will be listed here.

Abstract

Background: The links among smoking, inflammation, and cardiovascular disease (CVD) are well established. Several studies have demonstrated that quitting smoking reverses the risk of coronary heart disease within 5 to 10 years. However, the immediate effects of quitting smoking on inflammatory biomarkers associated with CVD risk have not been well described.

Methods: In this pilot study, we examined a panel of circulating inflammatory biomarkers associated with CVD in "at-risk" women during the smoking cessation program. Forty-six women enrolled in a smoking cessation program consented to attend four study visits over 6 to 7 weeks. Health/medical information and blood were collected at each visit. Circulating levels of C-reactive protein (CRP), tumor necrosis factor (TNF), interleukin (IL)-6, soluble TNF receptor (sTNFR)-I, sTNFR-II, and soluble vascular cell adhesion molecule (sVCAM)-1 were measured, and changes between baseline levels (visit 1, while smoking) and visits 2 through 4 were determined.

Results: Significant reductions in circulating levels of TNF, sTNFR-I, sTNFR-II, and sVCAM-1 were observed among participants over the course of the smoking cessation program. Serum levels of both IL-6 and CRP declined during the smoking cessation program; the changes were not statistically significant, however.

Conclusions: These findings suggest there are rapid consequences of smoking cessation on inflammatory biomarkers in women at risk for CVD. Additional, larger studies including diverse smokers desiring to quit are required to confirm changes in "measurable milestones" that could serve as motivating factors to assist smokers to quit.

Citing Articles

The brain structure underlying the nonlinear association between early-life tobacco smoke exposure and the risk for cognitive decline and dementia in adulthood: a large prospective cohort study.

Lin C, Lin F, Yang K, Zhong Y, Luo Y, Chen H BMC Public Health. 2025; 25(1):216.

PMID: 39827101 PMC: 11742755. DOI: 10.1186/s12889-025-21305-6.

Effect of heavy cigarette and water pipe smoking on antioxidants and lipids in Sudanese male smokers: a case-control study.

Ahmed A, Ibrahim A Afr Health Sci. 2023; 22(3):125-132.

PMID: 36910389 PMC: 9993274. DOI: 10.4314/ahs.v22i3.15.

The influence of inflammation on cardiovascular disease in women.

Kottilil S, Mathur P Front Glob Womens Health. 2022; 3:979708.

PMID: 36304737 PMC: 9592850. DOI: 10.3389/fgwh.2022.979708.

Association of Duration of Smoking Cessation or Cumulative Smoking Amount with Serum hs-CRP Level in Korean Adults: A Nationwide Population-Based Cross-Sectional Study.

Cho J, Lee D, Lee H Toxics. 2022; 10(9).

PMID: 36136498 PMC: 9501822. DOI: 10.3390/toxics10090533.

Smoking cessation reduces systemic inflammation and circulating endothelin-1.

Derella C, Tingen M, Blanks A, Sojourner S, Tucker M, Thomas J Sci Rep. 2021; 11(1):24122.

PMID: 34916543 PMC: 8677816. DOI: 10.1038/s41598-021-03476-5.

References

Willett W, Green A, Stampfer M, Speizer F, Colditz G, Rosner B . Relative and absolute excess risks of coronary heart disease among women who smoke cigarettes. N Engl J Med. 1987; 317(21):1303-9. DOI: 10.1056/NEJM198711193172102. View

Haywood K, Garratt A, Fitzpatrick R . Quality of life in older people: a structured review of generic self-assessed health instruments. Qual Life Res. 2005; 14(7):1651-68. DOI: 10.1007/s11136-005-1743-0. View

Huston J, Ochani M, Rosas-Ballina M, Liao H, Ochani K, Pavlov V . Splenectomy inactivates the cholinergic antiinflammatory pathway during lethal endotoxemia and polymicrobial sepsis. J Exp Med. 2006; 203(7):1623-8. PMC: 2118357. DOI: 10.1084/jem.20052362. View

Heron M, Smith B . Deaths: leading causes for 2003. Natl Vital Stat Rep. 2007; 55(10):1-92. View

Yudkin J, Kumari M, Humphries S, Mohamed-Ali V . Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?. Atherosclerosis. 2000; 148(2):209-14. DOI: 10.1016/s0021-9150(99)00463-3. View

Dobson A, Alexander H, Heller R, Lloyd D . How soon after quitting smoking does risk of heart attack decline?. J Clin Epidemiol. 1991; 44(11):1247-53. DOI: 10.1016/0895-4356(91)90157-5. View

Lofdahl J, Wahlstrom J, Skold C . Different inflammatory cell pattern and macrophage phenotype in chronic obstructive pulmonary disease patients, smokers and non-smokers. Clin Exp Immunol. 2006; 145(3):428-37. PMC: 1809704. DOI: 10.1111/j.1365-2249.2006.03154.x. View

Mohiuddin S, Mooss A, Hunter C, Grollmes T, Cloutier D, Hilleman D . Intensive smoking cessation intervention reduces mortality in high-risk smokers with cardiovascular disease. Chest. 2007; 131(2):446-52. DOI: 10.1378/chest.06-1587. View

Surewicz K, Cross J, Hejal R, Templeton D, Rich E, Toossi Z . Differential activation of MAP kinase signaling pathways and nuclear factor-kappaB in bronchoalveolar cells of smokers and nonsmokers. Mol Med. 2001; 7(3):177-85. PMC: 1950026. View

10.

Walters M, Paul-Clark M, McMaster S, Ito K, Adcock I, Mitchell J . Cigarette smoke activates human monocytes by an oxidant-AP-1 signaling pathway: implications for steroid resistance. Mol Pharmacol. 2005; 68(5):1343-53. DOI: 10.1124/mol.105.012591. View

11.

Cesari M, Penninx B, Newman A, Kritchevsky S, Nicklas B, Sutton-Tyrrell K . Inflammatory markers and cardiovascular disease (The Health, Aging and Body Composition [Health ABC] Study). Am J Cardiol. 2003; 92(5):522-8. DOI: 10.1016/s0002-9149(03)00718-5. View

12.

Gonzalez M, Selwyn A . Endothelial function, inflammation, and prognosis in cardiovascular disease. Am J Med. 2003; 115 Suppl 8A:99S-106S. DOI: 10.1016/j.amjmed.2003.09.016. View

13.

Madsen C, Nafstad P, Eikvar L, Schwarze P, Ronningen K, Haaheim L . Association between tobacco smoke exposure and levels of C-reactive protein in the Oslo II Study. Eur J Epidemiol. 2007; 22(5):311-7. DOI: 10.1007/s10654-007-9121-6. View

14.

Pai J, Pischon T, Ma J, Manson J, Hankinson S, Joshipura K . Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med. 2004; 351(25):2599-610. DOI: 10.1056/NEJMoa040967. View

15.

Heinrich P, Castell J, Andus T . Interleukin-6 and the acute phase response. Biochem J. 1990; 265(3):621-36. PMC: 1133681. DOI: 10.1042/bj2650621. View

16.

Chalmers G, MacLeod K, Thomson L, Little S, McSharry C, Thomson N . Smoking and airway inflammation in patients with mild asthma. Chest. 2001; 120(6):1917-22. DOI: 10.1378/chest.120.6.1917. View

17.

Barbieri S, Weksler B . Tobacco smoke cooperates with interleukin-1beta to alter beta-catenin trafficking in vascular endothelium resulting in increased permeability and induction of cyclooxygenase-2 expression in vitro and in vivo. FASEB J. 2007; 21(8):1831-43. DOI: 10.1096/fj.06-7557com. View

18.

Bernik T, Friedman S, Ochani M, DiRaimo R, Susarla S, Czura C . Cholinergic antiinflammatory pathway inhibition of tumor necrosis factor during ischemia reperfusion. J Vasc Surg. 2002; 36(6):1231-6. DOI: 10.1067/mva.2002.129643. View

19.

Tuomisto K, Jousilahti P, Sundvall J, Pajunen P, Salomaa V . C-reactive protein, interleukin-6 and tumor necrosis factor alpha as predictors of incident coronary and cardiovascular events and total mortality. A population-based, prospective study. Thromb Haemost. 2006; 95(3):511-8. DOI: 10.1160/TH05-08-0571. View

20.

Wouters E, Groenewegen K, Dentener M, Vernooy J . Systemic inflammation in chronic obstructive pulmonary disease: the role of exacerbations. Proc Am Thorac Soc. 2007; 4(8):626-34. DOI: 10.1513/pats.200706-071TH. View